Protective role of dairy and its constituents on vascular function independent of blood pressure-lowering activities.

Nutr Rev

K.D. Ballard is with the Division of Cardiology, Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut, USA. R.S. Bruno is with the Human Nutrition Program, Department of Human Sciences, The Ohio State University, Columbus, Ohio, USA.

Published: January 2015

Greater intakes of dairy are frequently associated with reduced risk of cardiovascular disease. These observational studies have served as the basis for controlled interventions aimed at defining the cardioprotective mechanisms of dairy. Understanding these relationships is of public health importance because most of the US population fails to meet dietary recommendations for dairy, suggesting that many individuals could lower their cardiovascular disease risk by relatively simple dietary modification. Clinical studies investigating the acute ingestion of dairy or its constituents, including short-term (≤2 week) supplementation studies or those assessing postprandial responses, have largely shown benefits on vascular function without concomitant improvements in blood pressure. Chronic interventions have been less conclusive, with some showing benefits and others indicating a lack of improvement in vascular function regardless of blood pressure changes. Vasoprotective activities of dairy are likely mediated through improvements in nitric oxide bioavailability, oxidative stress, inflammation, and insulin resistance. Future controlled studies are needed to determine if these health benefits are mediated directly by dairy or indirectly by displacing other dietary components that otherwise impair vascular health.

Download full-text PDF

Source
http://dx.doi.org/10.1093/nutrit/nuu013DOI Listing

Publication Analysis

Top Keywords

vascular function
12
dairy constituents
8
cardiovascular disease
8
blood pressure
8
dairy
7
protective role
4
role dairy
4
vascular
4
constituents vascular
4
function independent
4

Similar Publications

Superficial temporal artery and middle cerebral artery (STA-MCA) bypass surgery is an effective method to enhance cerebral blood flow (CBF) in ischemic patients. However, the effectiveness of various bypass techniques varies with the diversity of Circle of Willis (CoW) structures. This study aims to develop a physiologically realistic hemodynamic model to optimize STA-MCA bypass planning for cerebral ischemia patients with different CoW structures.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to explore how plasma α-synuclein levels relate to cerebral blood flow in Parkinson's disease patients who experience freezing of gait (FOG).
  • A total of 120 Parkinson's patients were assessed for FOG and divided into two groups: those with FOG and those without.
  • Results showed that patients with FOG had slower blood flow in key arteries and higher α-synuclein levels, indicating that these factors independently increase the risk of FOG in Parkinson's disease.
View Article and Find Full Text PDF

Pulmonary hypertension (PH) stands as a tumor paradigm cardiovascular disease marked by hyperproliferation of cells and vascular remodeling, culminating in heart failure. Complex genetic and epigenetic mechanisms collectively contribute to the disruption of pulmonary vascular homeostasis. In recent years, advancements in research technology have identified numerous gene deletions and mutations, in addition to , that are closely associated with the vascular remodeling process in PH.

View Article and Find Full Text PDF

Background: Despite the development of effective pulmonary vasodilators, the prognosis for patients with pulmonary hypertension (PH) remains poor, particularly in medication-refractory patients. Catheter-based pulmonary artery denervation (PADN) is an emerging therapeutic strategy targeting the sympathetic nervous system in various types of PH. However, data on its safety and efficacy in refractory patients with PH who truly require non-pharmacotherapy are lacking.

View Article and Find Full Text PDF

Background: Because Regnase-1, encoded by , suppresses the development of pulmonary arterial hypertension (PAH) by controlling pro-inflammatory cytokines, we aimed to identify variants in patients with PAH.

Methods And Results: We analyzed whole-genome sequence data of patients with PAH to search for disease-associated variants. The Regnase-1 p.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!